Clinical Trial

A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is testing the effect of a new study medicine NNC0194-0499 in type 1 diabetes. The purpose of the study is to compare the effect of NNC0194-0499 on the blood sugar levels of participants with type 1 diabetes when taken in combination with semaglutide or placebo. All participants will receive standard of care insulin treatment. The study will last for about 36 weeks.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-24; most recent amendment 2026-03-30.
Status change: Recruiting → Active, Not Recruiting 2026-03-30
Trial Details
NCT Number NCT07087795
Lead Sponsor Novo Nordisk A/S
Conditions Diabetes Mellitus, Type 1
Enrollment 96 participants
Start Date 2025-07-01
Primary Completion 2026-09-12 (estimated)
Study Completion 2026-09-25 (estimated)
Updated on ClinicalTrials.gov 2026-08-13